Rani Therapeutics: ‘We’ve Tested A Dozen Molecules, All Of Them Have Worked’
CEO Talat Imran: ‘I Think We Get An Inbound Partner Interest Every Week At This Point’
In an exclusive interview with Generics Bulletin, Talat Imran, CEO of oral-dose biologics player Rani Therapeutics, talks adalimumab, partnering opportunities and financing, in the wake of kicking off pre-clinical development of its RT-111 proposed biosimilar to Janssen’s Stelara (ustekinumab) contained in its proprietary RaniPill Go ‘robotic’ capsule.
You may also be interested in...
Celltrion has doubled down on its alliance with Rani Therapeutics for oral pill versions of biosimilars by adding adalimumab to an existing collaboration covering ustekinumab.
United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.
California-based Rani Therapeutics has provided several key pipeline updates and targets, ahead of plans to accelerate development of its proprietary RaniPill Go ‘robotic’ capsule technology in 2023.